ArticleThe Lancet regional health. Europe2024
Genetic predisposition and antipsychotic treatment effect on metabolic syndrome in schizophrenia: a ten-year follow-up study using the Estonian Biobank.
Article in The Lancet regional health. Europe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Can Polygenic Risk Scores for Metabolic Syndrome Contribute to Long-Term Syndrome Development in First-Episode Psychosis Patients? A Naturalistic 21-Year Follow-Up Study.Schizophrenia bulletin · 2026Article
- Evidence for overlapping genetic architecture between lifestyle factors and severe mental disorders with different patterns across diagnoses.EBioMedicine · 2026Article
- Prescribed hormonal contraceptive use trends in the Estonian Biobank: A longitudinal observational study.PLoS medicine · 2026Observational
- Lipid-lowering and glucose-lowering drug targets differentially modulate antipsychotic treatment efficacy in schizophrenia.Cell reports. Medicine · 2026Article
- Interpreting artificial neural networks to detect genome-wide association signals for complex traits.NAR genomics and bioinformatics · 2026Article
- Repositioning candidate gene approaches in the post-GWAS era: a clinical perspective from psychiatric pharmacogenetics.Frontiers in genetics · 2026Article
- Integrative Bioinformatics Analysis Reveals Pathogenesis Biomarkers for Clozapine-Induced Metabolic Syndrome.Alpha psychiatry · 2025Article
- Genetic influences on antidepressant side effects: a CYP2C19 gene variation and polygenic risk study in the Estonian Biobank.European journal of human genetics : EJHG · 2025Article
- Associations of Genetic Liability to Six Psychiatric Disorders With Cardiometabolic Diseases.medRxiv : the preprint server for health sciences · 2025Article
- Genome-wide associations with metabolic syndrome among UK Biobank participants reporting use of second-generation antipsychotics.Pharmacotherapy · 2025Article
- Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data.BMC medicine · 2025Article
- Comorbidity patterns and immune-metabolic differences in patients with acute-episode of schizophrenia spectrum disorders.Schizophrenia (Heidelberg, Germany) · 2025Article
- Association between genetic liability to physical health conditions and comorbidities in individuals with severe mental illness: an analysis of two cross-sectional observational studies in the UK.The lancet. Psychiatry · 2025Observational
- The Estonian Biobank's journey from biobanking to personalized medicine.Nature communications · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Schizophrenia (SCZ) patients exhibit 30% higher prevalence of metabolic syndrome (MetS) compared to the general population with its suboptimal management contributing to increased mortality. Large-scale studies providing real-world evidence of the underlying causes remain limited. Methods: To address this gap, we used real-world health data from the Estonian Biobank, spanning a median follow-up of ten years, to investigate the impact of genetic predisposition and antipsychotic treatment on the development of MetS in SCZ patients. Specifically, we set out to characterize antipsychotic treatment patterns, genetic predisposition of MetS traits, MetS prognosis, and body mass index (BMI) trajectories, comparing SCZ cases (n = 677) to age- and sex-matched controls (n = 2708). Findings: SCZ cases exhibited higher genetic predisposition to SCZ (OR = 1.75, 95% CI 1.58-1.94), but lower polygenic burden for increased BMI (OR = 0.88, 95% CI 0.88-0.96) and C-reactive protein (OR = 0.88, 95% CI 0.81-0.97) compared to controls. While SCZ cases showed worse prognosis of MetS (HR 1.95, 95% CI 1.54-2.46), higher antipsychotic adherence within the first treatment year was associated with reduced long-term MetS incidence. Linear mixed modelling, incorporating multiple BMI timepoints, underscored the significant contribution of both, antipsychotic medication, and genetic predisposition to higher BMI, driving the substantially upward trajectory of BMI in SCZ cases. Interpretation: These findings contribute to refining clinical risk prediction and prevention strategies for MetS among SCZ patients and emphasize the significance of incorporating genetic information, long-term patient tracking, and employing diverse perspectives when analyzing real-world health data. Funding: EU Horizon 2020, Swedish Research Council, Estonian Research Council, Estonian Ministry of Education and Research, University of Tartu.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.